[RAS mutations at the molecular tumor conference]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The rat sarcoma (RAS) gene family is frequently mutated in various cancers, driving disease progression and influencing treatment outcomes.
• Despite over 30 years of research, targeting mutated RAS proteins has remained a significant challenge in oncology.
• RAS mutations are routinely detected in molecular diagnostics, highlighting their clinical relevance.

Purpose of the Study:

• To review the current landscape of RAS-targeted therapies.
• To discuss recent advancements and emerging strategies for targeting "undruggable" RAS mutations.
• To emphasize the clinical importance of RAS mutation detection in cancer diagnostics and treatment.

Main Methods:

• Literature review of preclinical and clinical studies on RAS-targeted therapies.
• Analysis of recent advancements in drug discovery and development targeting RAS.
• Synthesis of information on the role of RAS mutations in cancer pathogenesis and therapy response.

Main Results:

• Novel therapeutic strategies targeting RAS are showing promise in clinical trials.
• Recent breakthroughs have enabled the development of drugs for previously undruggable RAS mutations.
• The detection of RAS mutations is an established part of routine cancer diagnostics.

Conclusions:

• Targeting RAS mutations represents a rapidly evolving field with significant therapeutic potential.
• Emerging therapies offer new hope for patients with RAS-driven cancers.
• Continued research and development are crucial for overcoming challenges in RAS-targeted therapy.